Ancora Heart Raises $80M To Support Ongoing Trial To Treat Heart Failure Patients
Ancora Heart will use the new funding to accelerate its pivotal trial of the AccuCinch ventricular restoration system for treating heart failure patients with reduced ejection fraction.
You may also be interested in...
The funds will support expanded commercialization of the company’s baroreflex activation stimulation technology to treat heart failure in patients with a low left-ventricular ejection fraction.
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.
The UK-based company said it will use the new funding to advance commercialization of its daytime treatment for mild sleep apnea and snoring.